Key Takeaways
- Nine leading European pharmaceutical companies have written to national leaders.
- The companies claim Europe is losing ground to US and Chinese rivals.
- The letter calls for action to safeguard the future of European drugmakers.
Nine of Europe's largest pharmaceutical companies, including AstraZeneca, GSK, and Novo Nordisk, have penned a letter to national leaders, expressing concerns about the continent's declining competitiveness in the global drug development sector.
The letter, addressed to Andy Burnham and other European national leaders, highlights the challenges faced by European drugmakers, particularly in comparison to their American and Chinese counterparts.
The companies argue that Europe is 'losing ground' in developing new drugs and attracting investment, a situation they believe is detrimental to the future of their businesses.
In their letter, the chairmen of the companies emphasized the need for immediate action to address these issues, suggesting that inaction could lead to further erosion of Europe's position in the global pharmaceutical landscape.
The letter calls for a comprehensive strategy to support research and development, enhance regulatory frameworks, and attract investment to ensure that European drugmakers remain competitive.
The companies also highlighted the importance of collaboration between governments, academia, and industry to foster innovation and maintain Europe's leading position in the pharmaceutical sector.
By addressing these concerns, the letter aims to prevent the further decline of European pharmaceutical companies and ensure that the continent remains a leader in drug development.
The letter underscores the urgency of the situation, with the companies warning that without intervention, Europe's pharmaceutical industry could face significant challenges in the coming years.
